AstraZeneca (NYSE:AZN) had its price objective upped by analysts at Sanford C. Bernstein from $40.00 to $42.00 in a report released on Monday. The firm presently has an “outperform” rating on the stock. Sanford C. Bernstein’s price target would indicate a potential upside of 20.27% from the company’s previous close.
AZN has been the subject of several other research reports. JPMorgan Chase & Co. upgraded AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Leerink Swann increased their price target on AstraZeneca from $31.00 to $34.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. Zacks Investment Research downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Credit Suisse Group upgraded AstraZeneca from a “neutral” rating to an “outperform” rating in a research note on Monday, October 16th. Finally, BMO Capital Markets set a $38.00 target price on AstraZeneca and gave the stock a “buy” rating in a research note on Wednesday, January 10th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $34.91.
AstraZeneca (NYSE AZN) traded down $0.98 during mid-day trading on Monday, hitting $34.92. The stock had a trading volume of 945,863 shares, compared to its average volume of 3,592,361. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. The company has a market cap of $90,914.66, a P/E ratio of 14.78, a price-to-earnings-growth ratio of 2.78 and a beta of 0.70. AstraZeneca has a 12 month low of $27.71 and a 12 month high of $36.70.
Institutional investors and hedge funds have recently modified their holdings of the company. WFG Advisors LP boosted its position in shares of AstraZeneca by 36.0% during the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after acquiring an additional 984 shares during the last quarter. Valeo Financial Advisors LLC bought a new stake in shares of AstraZeneca during the 3rd quarter valued at about $133,000. Wealthcare Advisory Partners LLC bought a new stake in shares of AstraZeneca during the 3rd quarter valued at about $184,000. Quadrant Capital Group LLC boosted its position in shares of AstraZeneca by 18.4% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after acquiring an additional 846 shares during the last quarter. Finally, Clean Yield Group bought a new stake in shares of AstraZeneca during the 4th quarter valued at about $205,000. Hedge funds and other institutional investors own 14.79% of the company’s stock.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.